Eloxx Pharmaceuticals

950 Winter Street
Waltham
Massachusetts
02451
United States

Tel: 1-781-577-5300

About Eloxx Pharmaceuticals

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.

YEAR FOUNDED: 2013

LEADERSHIP:

Chairman of the Board & CEO: Bob Ward
CMO: Dr. Pedro Huertas
CFO: Gregory Weaver
VP CMC: John van Duzer
Investor Relations: Barbara Ryan
VP Translational Science: Neal Sharpe

102 articles about Eloxx Pharmaceuticals

Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021

3/4/2021

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Cystic FibrosisPublication titled: “Targeting G542X CFTR Nonsense Alleles With ELX-02 Restores CFTR Function in Human-Derived Intestinal Organoids”

2/9/2021

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that a scientific manuscript titled: “ Targeting G542X CFTR Nonsense Alleles With ELX-02 Restores CFTR Function in Human-Derived Intestinal Organoids ” was p
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Development

1/26/2021

Eloxx Pharmaceuticals announced a Publication titled: “ A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects”
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology

1/20/2021

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that a scientific manuscript titled: “Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients,”
Clinical Catch-Up: January 11-15

1/18/2021

The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical Trial Program

1/13/2021

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins,
Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

11/18/2020

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, is pleased to announce that Dr. Gregory Williams, Chief Executive Officer of Eloxx, will participate in a fireside chat and host one-on-one meetings with investors at the Piper Sandler 32nd Annual Virtual Growth Conference.
Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update

11/5/2020

Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 2021
Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It’s ERSG Library In Two Leading Journals

10/27/2020

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins,today announced that two scientific manuscripts have been published in two leading journals
Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference

10/22/2020

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it presented data from two scientific abstracts at the North American Cystic Fibrosis Virtual Conference (NACFC).
Eloxx Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020

10/15/2020

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET
Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant

9/14/2020

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, announced that Professor Eitan Kerem, M.D. has joined the Company as a Senior Consultant.
Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference in October

8/26/2020

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that two abstracts will be presented at the North American Cystic Fibrosis Conference (NACFC) to be held virtually starting on October 7, 2020. The two abstracts w
Clinical Catch-Up: August 10-14

8/17/2020

It was a very busy week for clinical trial updates. Here’s a look.
Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 Pandemic

8/12/2020

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that enrollment in its Phase 2 clinical trial for ELX-02 in cystic fibrosis has resumed at certain clinical sites in the U.S. after being temporarily paused in response to the COVID-19
Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update

8/6/2020

Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel after being temporarily paused due to the COVID-19 pandemic U.S. FDA has granted orphan drug designation for ELX-02 for the treatment of cystic fibrosis Completing enrollment in our Phase 2 cystic fibrosis clinical trials and reporting top line data remain our highest priorities Preclinical studies continuing to advance in autosomal dominant polycystic kidney disease (ADP
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis

8/4/2020

ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency
Eloxx Pharmaceuticals to Present at the 40th Annual Canaccord Genuity Virtual Growth Conference on August 13th, 2020

7/28/2020

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Dr. Gregory Williams, Chief Executive Officer of Eloxx, will make a presentation and host one-on-one meetings with investors at the 40th Annual Canaccord Gen
Eloxx Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020Company management to host a webcast and conference call to provide a business update and review financial results at 2:00 p.m. ET

7/21/2020

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it will release its second quarter 2020 financial and operational results and host a conference call and live webcast on Thursday, August 6, 2020.
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Pharmacology and Experimental TherapeuticsELX-02 mediates read-through of premature stop codons while maintaining the fidelity of native stop codons

7/15/2020

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that a scientific manuscript titled: “ELX-02 Generates Protein via Premature Stop Codon Read-through Without Inducing Native Stop Codon Read-through Protein”